一个TROP2/Claudin程序调解免疫排斥以阻止乳腺癌检查点封锁
Bogang Wu1, Win Thant1, Elena Bitman1
1Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.
bioRxiv : the preprint server for biology
|December 16, 2024
概括
热囊细胞表面抗原2 (TROP2) 通过调节紧密的结节来驱动三阴性乳腺癌 (TNBC) 的免疫排除. 准TROP2增强了T细胞透和TNBC中的免疫治疗反应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
背景情况:
- 免疫排除阻碍了抗瘤免疫力和免疫疗法的有效性.
- 在三阴性乳腺癌 (TNBC) 中免疫排除的基础机制尚未完全理解.
研究的目的:
- 研究热囊细胞表面抗原2 (TROP2) 在TNBC内的免疫排除中的作用.
- 探索TROP2作为增强免疫疗法反应的潜在治疗标.
主要方法:
- 使用功能丧失和复制实验 in vivo.
- 采用了一个人性化的TROP2同基因TNBC模型.
- 分析了TROP2表达与T细胞透和患者结果的相关性.
主要成果:
- TROP2表达与T细胞透相反相关,并且与TNBC中较差的结果有关.
- 丢失TROP2会放松紧密结蛋白的调节,促进T细胞的透.
- 用抗体 (hRS7) 向TROP2,通过改善T细胞的可访问性和功能,增强了抗PD1反应.
结论:
- 在TNBC中,TROP2在障碍介导免疫排除中发挥着关键作用.
- 针对TROP2是一种可行的策略,可以克服免疫排斥并提高免疫疗法的有效性.
- 在乳腺癌中,TROP2表达预测了对抗PD1治疗的反应.
关键词:
抗体 - 药物结合物在PD-1中使用PD-1.这就是TROP2的原因.抗瘤免疫力 免疫力免疫检查点封锁封锁免疫排斥 免疫排斥萨基图祖马布 (Sacituzumab) govitecan可以使用.紧密的交叉路口紧密的连接三重阴性乳腺癌是什么瘤免疫的微环境更多相关视频
相关概念视频
Tumor Immunotherapy
475
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
475
T Cell Activation and Clonal Selection
655
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
655
Tight Junctions
5.2K
Tight junctions are molecular seals between cells that prevent the leaking of fluids, ions, and other small solutes across cavities and compartments in multicellular organisms. They are mainly composed of claudin and occludin transmembrane proteins, and other proteins such as tricellulin and JAM (junctional adhesion molecule). All these proteins are 4-pass transmembrane proteins, except JAM, which is a single-pass transmembrane protein belonging to the immunoglobulin superfamily. The...
5.2K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K


